Stock Market Resilience: Celularity Inc's (CELU) Remarkable Turnaround
Stock Market Resilience: Celularity Inc's (CELU) Remarkable Turnaround
During Tuesday's extended trading session, Celularity Inc. (NASDAQ: CELU) saw a notable uptick in its stock price, gaining 23.57 percent to $7.23 per share. In contrast to CELU's performance during the regular session, which saw a 15.30% loss and close at $5.89, the stock saw a rise in value as traders anticipated a noteworthy development.
在週二的延期交易時段中，Celularity Inc.（納斯達克股票代碼：CELU）的股價顯著上漲，上漲23.57％，至每股7.23美元。與CELU在常規交易中的表現形成鮮明對比的是，CELU的跌幅爲15.30％，收於5.89美元，而由於交易員預計會出現值得注意的發展，該股的價值有所上漲。
Dr. Robert Hariri, M.D., Ph.D., the founder and CEO of Celularity (CELU), will deliver the keynote speech at the Society for Brain Mapping and Therapeutics (SBMT) Annual World Congress on March 16, 2024.
Celularity（CELU）的創始人兼首席執行官羅伯特·哈里里博士，醫學博士，博士將於2024年3月16日在腦映射與治療學會（SBMT）年度世界大會上發表主題演講。
Dr. Hariri's keynote address, "Prospects of Cell and Immunotherapy: From Oncology to Neurodegenerative Pathologies," will examine the wide range of uses for cellular immunotherapy, extending beyond oncological settings to include potential applications in neuroinflammatory and degenerative diseases such as multiple sclerosis and Parkinson's disease.
哈里里博士的主題演講 “細胞和免疫療法的前景：從腫瘤學到神經退行性病理學” 將探討細胞免疫療法的廣泛用途，不僅限於腫瘤學環境，還包括在多發性硬化症和帕金森氏病等神經炎症和退行性疾病中的潛在應用。
Additionally, Dr. Hariri will participate in two other keynote panel discussions during the Congress: the first on March 14, focusing on the "Emergence of Neurotech: Convergence of Cellular Therapy, Medical Devices, and Policy," and the second on March 16, exploring the intersection of "Cancer, Neurodegenerative Ailments, and Cellular Interventions."
此外，哈里里博士還將在大會期間參加另外兩場主題小組討論：第一次在3月14日舉行，重點是 “神經科技的興起：細胞療法、醫療器械和政策的融合”；第二次於3月16日舉行，探討 “癌症、神經退行性疾病和細胞干預” 的交叉點。
Within the rapidly evolving landscape of cellular medicine, Celularity is dedicated to advancing transformative therapies for individuals afflicted with neurological ailments, leveraging its proprietary technology platform, which harnesses placental-derived cells, biological materials, and by-products.
在快速變化的細胞醫學領域中，Celularity致力於利用其利用胎盤衍生細胞、生物材料和副產物的專有技術平台，推進針對神經系統疾病患者的變革性療法。
Celularity has conducted extensive research in neuroinflammatory conditions, including multiple sclerosis, and has investigated the potential of cellular and regenerative therapies in addressing age-related cognitive decline.
Celularity對包括多發性硬化症在內的神經炎症狀進行了廣泛的研究，並研究了細胞和再生療法在解決與年齡相關的認知能力下降方面的潛力。
Given the collaborative endeavors facilitated by the SBMT and World Brain Mapping Foundation (WBMF), fostering synergy between academia and industry while presenting viable commercial and investment prospects, the Annual World Congress serves as an ideal forum for discourse on our ongoing research endeavors.
鑑於SBMT和世界大腦映射基金會（WBMF）推動的合作努力，促進了學術界和工業界之間的協同效應，同時提供了可行的商業和投資前景，因此年度世界大會是討論我們正在進行的研究工作的理想論壇。
The trajectory of cellular and regenerative medicine is poised for substantial evolution through its convergence with nanotechnology, predictive modeling, advanced devices, imaging techniques, AI integration, and the advent of augmented and virtual reality applications.
通過與納米技術、預測建模、先進設備、成像技術、人工智能集成以及增強現實和虛擬現實應用程序的出現，細胞和再生醫學的發展軌跡有望發生實質性的演變。
Guided by Dr. Hariri's visionary leadership, Celularity is steadfast in its commitment to advancing the frontiers of cellular therapeutics, emerging as a frontrunner in this transformative domain.
在哈里里博士富有遠見的領導層的指導下，Celularity堅定不移地致力於推進細胞療法的前沿，成爲這一變革領域的領跑者。
譯文內容由第三人軟體翻譯。